Martin & Harris company logo

Martin & Harris Share Price

PHYSICAL

PUBLIC LIMITED

Price Chart

High

₹1,930

Low

₹774.6

Return

-59.61%

Buy Sell Martin & Harris Unlisted Shares

As of November 20, 2026, Martin and Harris Laboratories Unlisted Shares are available at ₹779.60 per share, with a face value of ₹10.00 per share, a 52-week high of ₹920.00 and a 52-week low of ₹774.00. The minimum lot size is 220 shares, and the shares can be held in dematerialised form through NSDL.

ISIN

info icon

INE03VV01015

Face Value

info icon

10

Total Shares

info icon

39,96,040

Market Cap

info icon

311.53 Cr

Profit After Tax

info icon

40.43 Cr

Total Revenue

info icon

146.15 Cr

P/E

info icon

7.71

P/B

info icon

0.56

Sector

info icon

Health Care

Sub-sector

info icon

Pharmaceuticals

Category

info icon

Micro Cap

Cashflow - Operations

info icon

19.57 Cr

About Martin & Harris

  • Established in 1993,Martin and Harris Labs Ltd. is a vertically integrated biopharmaceutical laboratory offering expertise in Drug Development and Pharmaceutical Manufacturing. A team of competent scientists providing innovative solutions for drug development, along with state-of-the-art manufacturing facilities work passionately towards providing high quality end products and services to ensure complete customer satisfaction.
  • The company has extensive manufacturing plants in Roorkee and Gagreth which have been built in accordance with the WHO GMP guidelines and these have separate quality control units and quality assurance functions to monitor the manufacturing quality of their products.
  • Martin and Harris Laboratories Ltd. operates state-of-the-art manufacturing facilities located at prime locations of the country in order to serve their domestic & International markets. These units have a multi-decade experience of manufacturing different complex dosage forms and specialty formulations
  • Pharmaceutical, medical, chemical, and botanical product manufacture are the main activities of Martin & Harris Laboratories Ltd.
  • In addition to its primary pharmaceutical business, it manages its money by investing in various opportunities that yield strong returns, such as mutual funds, listed and unlisted stocks, etc. Delite Infrastructure Limited, an investment arm of Martin & Harris, handles all the related operations.

Want to See a Detailed Investment Analysis?

Explore in-depth financial analysis, performance metrics, and key disclosures.

Martin & Harris Media

No News available for this company.

Frequently Asked Question (FAQs)

The annual report of Martin & Harris Ltd is available in the annual report section.
Lock-in period of Martin & Harris Unlisted Shares depends upon category of investors.
• 1. Venture Capital Funds or Alternate Investment Fund of Category -I or II, or Foreign Venture Capital Investor - lock-in Period of 6 months from the date of acquisition of Martin & Harris Unlisted Shares.
• 2. Other Investors (include Retail, HNIs or Body Corporate) lock-in Period of 6 months from the date of listing of IPO of Martin & Harris Unlisted Shares.
This new SEBI rule was introduced in the month of August-2021, wherein the SEBI has reduced the lock-in period previously from 1 year to 6 months to encourage more and more funds to be invested in startups which are going to public or IPO in near future. Reduction of lock-in is seen as big step and after that many PMS funds are advising their clients to invest in Pre-IPO shares to get the benefit of early stage investment.
Yes, buying and selling of unlisted shares in India is 100% legal.

Martin & Harris

₹ 779.6